Are pharmacotherapeutics effective for treating aphasia?

References

• Hillis AE. Aphasia: progress in the last quarter of a century. Neurology. 2007;69(2):200–213. doi: 10.1212/01.WNL.0000265600.69385.6F
   PubMed Web of Science ®Google Scholar
• Berthier ML. Ten Key reasons for continuing research on pharmacotherapy for post-stroke aphasia. Aphasiology. 2021;35(6):824–858. doi: 10.1080/02687038.2020.1769987
   Web of Science ®Google Scholar
• Sheppard SM, Sebastian R. Diagnosing and managing post-stroke aphasia. Expert Rev Neurother. 2021;21(2):221–234. doi: 10.1080/14737175.2020.1855976
   PubMed Web of Science ®Google Scholar
• Berthier ML, Dávila G. Pharmacotherapy for post-stroke aphasia: what are the options? Expert Opin Pharmacother. 2023;24(11):1221–1228. doi: 10.1080/14656566.2023.2221382
   PubMed Web of Science ®Google Scholar
• Dávila G, Torres-Prioris MJ, López-Barroso D, et al. Turning the spotlight to cholinergic pharmacotherapy of the human language system. CNS Drugs. 2023;37(7):599–637. doi: 10.1007/S40263-023-01017-4
   PubMed Web of Science ®Google Scholar
• Woodhead ZVJ, Crinion J, Teki S, et al. Auditory training changes temporal lobe connectivity in ‘Wernicke’s aphasia’: a randomised trial. J Neurol Neurosurg Psychiatry. 2017;88(7):586–594. doi: 10.1136/JNNP-2016-314621
   PubMed Web of Science ®Google Scholar
• Berthier ML, Pulvermüller F, Dávila G, et al. Drug therapy of post-stroke aphasia: a review of current evidence. Neuropsychol Rev. 2011;21(3):302–317. doi: 10.1007/s11065-011-9177-7
   PubMed Web of Science ®Google Scholar
• Cavanaugh R, Haley KL. Subjective communication difficulties in very mild aphasia. Am J Speech Lang Pathol. 2020;29(1S):437–448. doi: 10.1044/2019_AJSLP-CAC48-18-0222
   PubMedGoogle Scholar
• García AM, Welch AE, Mandelli ML, et al. Automated detection of speech timing alterations in autopsy-confirmed nonfluent/agrammatic variant primary progressive aphasia. Neurology. 2022;99(5):E500–E511. doi: 10.1212/WNL.0000000000200750
   PubMed Web of Science ®Google Scholar
• Small SL. Pharmacotherapy of aphasia. A critical review. Stroke. 1994;25(6):1282–1289. doi: 10.1161/01.STR.25.6.1282
   PubMed Web of Science ®Google Scholar
• Albert ML. Treatment of aphasia. Arch Neurol. 1998;55(11):1417–1419. doi: 10.1001/ARCHNEUR.55.11.1417
   PubMedGoogle Scholar
• Berthier ML, Edelkraut L, López-González FJ, et al. Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: a feasibility study. Brain Lang. 2023;236:105205. doi: 10.1016/j.bandl.2022.105205
   PubMed Web of Science ®Google Scholar
• Kiran S, Thompson CK. Neuroplasticity of language networks in aphasia: advances, updates, and future challenges. Front Neurol. 2019;10. doi: 10.3389/FNEUR.2019.00295
   Web of Science ®Google Scholar
• Staekenborg SS, Van Der Flier WM, Van Straaten ECW, et al. Neurological signs in relation to type of cerebrovascular disease in vascular dementia. Stroke. 2008;39(2):317–322. doi: 10.1161/STROKEAHA.107.493353
   PubMed Web of Science ®Google Scholar
• Román GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke. 2010;41(6):1213–1221. doi: 10.1161/STROKEAHA.109.570077
   PubMed Web of Science ®Google Scholar
• Stockbridge MD. Better language through chemistry: augmenting speech-language therapy with pharmacotherapy in the treatment of aphasia. Handb Clin Neurol. 2022;185:261–272. doi: 10.1016/B978-0-12-823384-9.00013-X
   PubMedGoogle Scholar
• Greener J, Enderby P, Whurr R. (2001) pharmacological treatment for aphasia following stroke. Cochrane Database Syst Rev. 2001. doi: 10.1002/14651858.CD000424
   PubMedGoogle Scholar
• Zhang J, Wei R, Chen Z, et al. Piracetam for aphasia in post-stroke patients: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2016;30(7):575–587. doi: 10.1007/S40263-016-0348-1
   PubMed Web of Science ®Google Scholar
• Franklin S, Harhen D, Hayes M, et al. Top 10 research priorities relating to aphasia following stroke. Aphasiology. 2018;32(11):1388–1395. doi: 10.1080/02687038.2017.1417539
   Web of Science ®Google Scholar
• Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141(7):1917–1933. doi: 10.1093/BRAIN/AWY132
   PubMed Web of Science ®Google Scholar
• Giacobini E, Cuello AC, Fisher A. Reimagining cholinergic therapy for Alzheimer’s disease. Brain. 2022;145(7):2250–2275. doi: 10.1093/BRAIN/AWAC096
   PubMed Web of Science ®Google Scholar
• Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer’s disease. Alzheimers Res Ther. 2011;3(3):22. doi: 10.1186/ALZRT84
   PubMed Web of Science ®Google Scholar
• Tocco M, Bayles K, Lopez OL, et al. Effects of memantine treatment on language abilities and functional communication: a review of data. Aphasiology. 2014;28(2):236–257. doi: 10.1080/02687038.2013.838617
   Web of Science ®Google Scholar
• Alva G, Isaacson R, Sadowsky C, et al. Efficacy of higher-dose 13.3 mg/24 h (15 cm 2) rivastigmine patch on the Alzheimer’s disease Assessment Scale-cognitive subscale: domain and individual item analysis. Int J Geriatr Psychiatry. 2014;29(9):920–927. doi: 10.1002/GPS.4080
   PubMed Web of Science ®Google Scholar
• Song J, Ahn IS, Kang HS, et al. Cognitive subdomain responses to galantamine in Alzheimer’s disease. J Nerv Ment Dis. 2014;202(3):253–259. doi: 10.1097/NMD.0000000000000107
   PubMed Web of Science ®Google Scholar
• van D CH, S CJ, A P, et al. The safety of inpatient health care. N Engl J Med. 2023;388(2):142–153. doi: 10.1056/NEJMOA2212948
   PubMed Web of Science ®Google Scholar
• Hausmann A, Chiabotti PS, Nasuti M, et al. Don’t forget primary progressive aphasia for anti-amyloid drugs: an estimation of eligible patients from the Lausanne memory center registry. Alzheimers Dement. 2023;19(11):5303–5304. doi: 10.1002/ALZ.13092
   PubMed Web of Science ®Google Scholar
• Šimić G, Mrzljak L, Fučić A, et al. Nucleus subputaminalis (Ayala): the still disregarded magnocellular component of the basal forebrain may be human specific and connected with the cortical speech area. Neuroscience. 1999;89(1):73–89. doi: 10.1016/S0306-4522(98)00304-2
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Lalehzari N, Rahmani F, et al. Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology. Neurology. 2019;92(14):E1580–E1588. doi: 10.1212/WNL.0000000000007247
   PubMed Web of Science ®Google Scholar
• Schaeverbeke J, Evenepoel C, Bruffaerts R, et al. Cholinergic depletion and basal forebrain volume in primary progressive aphasia. NeuroImage Clin. 2016;13:271–279. doi: 10.1016/J.NICL.2016.11.027
   PubMed Web of Science ®Google Scholar
• Teipel S, Raiser T, Riedl L, et al. Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex. 2016;83:124–135. doi: 10.1016/J.CORTEX.2016.07.004
   PubMed Web of Science ®Google Scholar
• Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cognit Disord. 2008;25(2):178–185. doi: 10.1159/000113034
   PubMed Web of Science ®Google Scholar
• Wallace SJ, Worrall L, Rose TA, et al. Measuring communication as a core outcome in aphasia trials: results of the ROMA-2 international core outcome set development meeting. Int J Lang Commun Disord. 2023;58(4):1017–1028. doi: 10.1111/1460-6984.12840
   PubMed Web of Science ®Google Scholar
• Berthier ML, Green C, Lara JP, et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65(5):577–585. doi: 10.1002/ana.21597
   PubMed Web of Science ®Google Scholar
• Gonzalez Rothi LJ, Fuller R, Leon SA, et al. Errorless practice as a possible adjuvant to donepezil in Alzheimer’s disease. J Int Neuropsychol Soc. 2009;15(2):311–322. doi: 10.1017/S1355617709090201
   PubMed Web of Science ®Google Scholar
• Walker-Batson D, Mehta J, Smith P, et al. Amphetamine and other pharmacological agents in human and animal studies of recovery from stroke. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:225–230. doi: 10.1016/J.PNPBP.2015.04.002
   PubMed Web of Science ®Google Scholar
• Berthier ML, De-Torres I, Paredes-Pacheco J, et al. Cholinergic potentiation and audiovisual repetition-imitation therapy improve speech production and communication deficits in a person with crossed aphasia by inducing structural plasticity in white matter tracts. Front Hum Neurosci. 2017;11. doi: 10.3389/fnhum.2017.00304
   Web of Science ®Google Scholar
• Berthier ML, Santana-Moreno D, Beltrán-Corbellini Á, et al. Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia. Aphasiology. 2022;36(11):1293–1311. doi: 10.1080/02687038.2021.1957082
   Web of Science ®Google Scholar
• Mineur YS, Picciotto MR. The role of acetylcholine in negative encoding bias: too much of a good thing? Eur J Neurosci. 2021;53(1):114–125. doi: 10.1111/EJN.14641
   PubMed Web of Science ®Google Scholar
• Stockbridge MD, Fridriksson J, Sen S, et al. Protocol for escitalopram and language intervention for subacute aphasia (ELISA): a randomized, double blind, placebo-controlled trial. PLoS One. 2021;16(12):e0261474. doi: 10.1371/JOURNAL.PONE.0261474
   PubMed Web of Science ®Google Scholar
• Stockbridge MD, Keser Z. Supporting post-stroke language and cognition with pharmacotherapy: tools for each phase of care. Curr Neurol Neurosci Rep. 2023;23(6):335–343. doi: 10.1007/S11910-023-01273-3
   PubMed Web of Science ®Google Scholar
• Torres-Prioris MJ, López-Barroso D, Paredes-Pacheco J, et al. Language as a threat: multimodal evaluation and interventions for overwhelming linguistic anxiety in severe aphasia. Front Psychol. 2019;10. doi: 10.3389/FPSYG.2019.00678
   PubMed Web of Science ®Google Scholar
• Berthier ML, Dávila G, López-Barroso D, et al. Pharmacological treatment of post-stroke cognitive deficits. In: Lazar R, Pavol M Browndyke J, editors. Neurovascular neuropsychology Second ed. (NY):Springer Science + Business Media. Behavioral Sciences; 2020. p. 465–500.
   Google Scholar
• Gorelick PB. Vascular Cognitive Impairment. In: Lazar R, Pavol M Browndyke J, editors. Neurovascular neuropsychology. Second ed. (NY): Springer Science + Business Media. Behavioral Sciences; 2020. p. 121–138.
   Google Scholar